An Assessment of the Steady-State Pharmacokinetic and Pharmacodynamic Profile of Tysabri 300 mg Following at Least 12 Monthly Infusions
收藏DataCite Commons2025-03-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003227/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective is to assess the pharmacokinetic (PK) profile of natalizumab (Tysabri) at steady state. The secondary objective is to assess the pharmacodynamics (PD) profile (α4 integrin saturation) of Tysabri at steady state.
提供机构：
Vivli
创建时间：
2018-10-27
